Beasley, G., Robert, C., Milhem, M. M., Sacco, J. J., Michels, J., In, G. K., … Wong, M. K. (2025). Primary efficacy, safety, survival, and initial biomarker data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE trial of RP1 plus nivolumab. In ANNALS OF SURGICAL ONCOLOGY (Vol. 32, pp. S43–S44).

Beasley, Georgia, Caroline Robert, Mohammed M. Milhem, Joseph J. Sacco, Judith Michels, Gino K. In, Eva Munoz-Couselo, et al. “Primary efficacy, safety, survival, and initial biomarker data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE trial of RP1 plus nivolumab.” In ANNALS OF SURGICAL ONCOLOGY, 32:S43–44, 2025.

Beasley G, Robert C, Milhem MM, Sacco JJ, Michels J, In GK, et al. Primary efficacy, safety, survival, and initial biomarker data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE trial of RP1 plus nivolumab. In: ANNALS OF SURGICAL ONCOLOGY. 2025. p. S43–4.

Beasley, Georgia, et al. “Primary efficacy, safety, survival, and initial biomarker data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE trial of RP1 plus nivolumab.” ANNALS OF SURGICAL ONCOLOGY, vol. 32, 2025, pp. S43–44.

Beasley G, Robert C, Milhem MM, Sacco JJ, Michels J, In GK, Munoz-Couselo E, Schadendorf D, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai KK, Lebbe C, Gaudy-Marqueste C, Middleton MR, Samson A, Zhu J, Viana M, Wong MK. Primary efficacy, safety, survival, and initial biomarker data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE trial of RP1 plus nivolumab. ANNALS OF SURGICAL ONCOLOGY. 2025. p. S43–S44.